Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL472058 | 0.82 | ALDH1A1 (0.54) | ALDH1A1MAPTMEN1KMT2ATDP1 | |
| SCHEMBL27298149 | 0.78 | ALDH1A1 (0.58) | ALDH1A1MAPTMEN1KMT2ATDP1 | |
| SCHEMBL5703968 | 0.78 | ALDH1A1 (0.58) | ALDH1A1MAPTMEN1KMT2ATDP1 | |
| SCHEMBL20377072 | 0.78 | ALDH1A1 (0.52) | ALDH1A1MAPTMEN1KMT2ATDP1 | |
| SCHEMBL28372644 | 0.78 | ALDH1A1 (0.58) | ALDH1A1MAPTMEN1KMT2ATDP1 | |
| SCHEMBL27594561 | 0.78 | MAPT (0.56) | ALDH1A1MAPTMEN1KMT2ATDP1 | |
| SCHEMBL1145203 | 0.78 | HSD17B10 (0.52) | ALDH1A1MAPTMEN1KMT2ATDP1 | |
| SCHEMBL7491094 | 0.78 | MAPT (0.56) | ALDH1A1MAPTMEN1KMT2ATDP1 | |
| SCHEMBL2853294 | 0.78 | ALDH1A1 (0.48) | ALDH1A1MAPTMEN1KMT2ATDP1 | |
| SCHEMBL1047553 | 0.77 | MAPT (0.70) | ALDH1A1MAPTMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060018914-A1 | Novel antibody conjugates reactive with human carcinomas | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-26 | — | — | US | disclosed |
| EP-0554708-B9 | Thioether conjugates | BRISTOL MYERS SQUIBB CO (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-0554708-B1 | Thioether conjugates | BRISTOL MYERS SQUIBB CO (US) | 2005-05-04 | — | — | EP | disclosed |
| US-20040043029-A1 | Novel antibodies reactive with human carcinomas | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-04 | — | — | US | disclosed |
| US-20040001801-A1 | Conjugates activated by cell surface proteases and therapeutic uses thereof | CORVAS INTERNATIONAL, INC. | 2004-01-01 | — | — | US | disclosed |
| EP-0926955-A4 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO INC (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20020192223-A1 | Novel antibody conjugates reactive with human carcinomas | HELLSTROM INGEGERG (US) | 2002-12-19 | — | — | US | disclosed |
| EP-0771209-B1 | NOVEL PEPTIDES | MERCK & CO INC (US) | 2002-09-04 | — | — | EP | disclosed |
| US-6391305-B1 | CONJUGATE WHICH COMPRISES CYTOTOXIC AGENT ATTACHED AT C-TERMINUS TO OLIGOPEPTIDE COMPRISING AMINO ACID SEQUENCE SELECTIVELY PROTEOLYTICALLY CLEAVED BY FREE PROSTATE SPECIFIC ANTIGEN, ALSO COMPRISING N-TERMINUS HYDROPHILIC BLOCKING GROUP | MERCK & CO., INC. | 2002-05-21 | — | — | US | disclosed |
| EP-0853483-A4 | NOVEL PEPTIDES | MERCK & CO INC (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-1998010651-A1 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO., INC. (US) | 1998-03-19 | — | — | WO | disclosed |
| US-5708146-A | ANTIBODIES AND DRUGS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0771209-A2 | NOVEL PEPTIDES | Merck & Co., Inc. (a New Jersey corp.) (US) | 1997-05-07 | — | — | EP | disclosed |
| WO-1997014416-A1 | CONJUGATES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. (US) | 1997-04-24 | — | — | WO | disclosed |
| US-5622929-A | ANTHRACYCLINE ANTIBIOTIC; ANTITUMOR AGENT BINDS WITH A TARGET CELL | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| WO-1997012624-A1 | NOVEL PEPTIDES | MERCK & CO., INC. (US) | 1997-04-10 | — | — | WO | disclosed |
| US-5606017-A | ANTITUMOR AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| US-5599686-A | OLIGOPEPTIDE COMPRISING SEQUENCE OF AMINO ACIDS RECOGNIZED AND SELECTIVELY PROTEOLYTICALLY CLEAVED BY FREE PROSTATE SPECIFIC ANTIGEN | MERCK & CO., INC. (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996000503-A1 | NOVEL PEPTIDES | MERCK & CO., INC. (US) | 1996-01-11 | — | — | WO | disclosed |
| EP-0554708-A1 | Thioether conjugates | Bristol-Myers Squibb Company (US) | 1993-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020192223-A1 | Novel antibody conjugates reactive with human carcinomas | LY96, FUCA2, FUCA1 | ALDH1A1 4180/4885MAPT 4580/4885MEN1 2837/4885 |
| US-20040043029-A1 | Novel antibodies reactive with human carcinomas | LY96, FUCA1, FUCA2 | ALDH1A1 4306/4885MAPT 4614/4885MEN1 2953/4885 |
| US-20040001801-A1 | Conjugates activated by cell surface proteases and therapeutic uses thereof | PLAUR, ENPEP, MASP2 | ALDH1A1 3216/4885MAPT 1302/4885MEN1 1569/4885 |
| US-20060018914-A1 | Novel antibody conjugates reactive with human carcinomas | LY96, FUCA2, FUCA1 | ALDH1A1 4153/4885MAPT 4502/4885MEN1 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.